

# Acta Balneologica

CZASOPISMO POLSKIEGO TOWARZYSTWA BALNEOLOGII I MEDYCYNY FIZYKALNEJ  
JOURNAL OF THE POLISH BALNEOLOGY AND PHYSICAL MEDICINE ASSOCIATION

TOM LXIII  
TOM LXIII

NUMER 1 (163)/2021  
NUMBER 1 (163)/2021

KWARTALNIK  
QUARTERLY

STYCZEŃ-MARZEC  
JANUARY-MARCH



Aluna Publishing

# Acta Balneologica

**REDAKCJA/EDITORIAL BOARD:**

prof. Włodzisław Kuliński  
– redaktor naczelny/Editor in Chief

**REDAKCJA ZAGRANICZNA/  
/FOREIGN EDITOR:**

Walter Karpinski

**REDAKTORZY TEMATYCZNI/  
/TOPIC EDITORS:**

dr Hanna Tomczak – rehabilitacja,  
balneologia, medycyna fizykalna  
dr Jacek Chojnowski – interna,  
balneologia, medycyna fizykalna  
dr Przemysław Adamczyk – urologia,  
balneologia, medycyna fizykalna  
dr Alicja Szymańska-Paszczuk –  
balneokosmetologia

**REDAKTORZY JĘZYKOWI/  
/LANGUAGE EDITORS:**

mgr Agnieszka Rosa  
prof. Oleksandr Pułyk

**REDAKTOR STATYSTYCZNY/  
/STATISTICAL EDITOR:**

mgr Ewa Guterman

**RADA NAUKOWA/  
/SCIENTIFIC BOARD:**

**Przewodnicząca/Chairwoman:**  
prof. Irena Ponikowska, Ciechocinek

**Członkowie/Members:**

prof. Krzysztof Błazejczyk, Warszawa  
prof. Mirosław Boruszczak, Gdańsk  
dr hab. Marek Chabior, Szczecin

prof. Grzegorz Cieślak, Bytom  
prof. Wojciech Ciężkowski, Wrocław  
dr hab. Dariusz Dobrzyński, Warszawa  
prof. Andrzej M. Fal, Warszawa  
prof. Tomasz Ferenc, Łódź  
prof. Wojciech Gruszczyński, Łódź  
dr Piotr Kalmus, Bydgoszcz  
dr Wojciech Kasprzak, Poznań  
prof. Jerzy Kiwerski, Warszawa  
prof. Robert Latosiewicz, Białystok  
dr Teresa Latour, Poznań  
prof. Krzysztof Marczewski, Zamość  
prof. Roman Ossowski, Bydgoszcz  
prof. Aleksander Ronikier, Warszawa  
prof. Włodzimierz Samborski, Poznań  
prof. Aleksander Sieroń, Bytom  
prof. Anna Straburzyńska-Lupa, Poznań  
dr Irena Walecka, Warszawa  
prof. Bohdan Wasilewski, Warszawa  
prof. Piotr Wiland, Wrocław  
prof. Jerzy Woy-Wojciechowski, Warszawa  
prof. Zygmunt Zdrojewicz, Wrocław

**MIĘDZYNARODOWA RADA NAUKOWA/  
/INTERNATIONAL SCIENTIFIC BOARD:**

prof. Yuko Agishi, Japan  
prof. Tomas Bender, Hungary  
prof. Sholpan Bulekbayeva, Kazakhstan  
prof. Pedro Cantista, Portugal  
prof. Nino Chikhladze, Georgia  
prof. Alina V. Chervinskaya, Russia  
prof. David Ferson, USA  
prof. Antonelle Fioravanti, Italy  
prof. Christopher Gutenbrunner, Germany  
prof. Giovanni Gurnari, Italy  
prof. Shigeko Inokuma, Japan  
prof. Zeki Karagulle, Turkey

dr Jan Lidaj, Slovak Republik  
prof. Olga G. Morozowa, Ukraine  
dr K'tso Nghargbu, Nigeria  
prof. Yoshinori Ohtsuko, Japan  
prof. Vitalii Pashkov, Ukraine  
prof. Oleksandr Pulyk, Ukraine  
prof. Alexander N. Razumov, Russia  
prof. Christian Francois Roques, France  
prof. Gabriel Reyes Secades, Nigeria  
prof. Gabriel Reyes Secades, Cuba  
dr hab. Urszula Smorag, Germany  
prof. Umberto Solimene, Italy  
prof. Olga Surdu, Romania  
prof. Sergo I. Tabagari, Georgia  
prof. Rosalba Vanni, Italy  
dr Khaj Vu, USA  
prof. Olha Yezhova, Ukraine

**WYDAWCA/PUBLISHER:**

Wydawnictwo Aluna  
ul. Przesmyckiego 29  
05-510 Konstancin Jeziorna  
[www.actabalneologica.pl](http://www.actabalneologica.pl)

**KOORDYNATOR PROJEKTU/  
/PROJECT COORDINATOR:**

MEDDOM PRESS  
tel. 604-208-453  
[barbadom@wp.pl](mailto:barbadom@wp.pl)

**OPRACOWANIE GRAFICZNE/  
/GRAPHIC DESIGN:**

Piotr Dobrzyński  
[www.poligrafia.nets.pl](http://www.poligrafia.nets.pl)

**PRENUMERATA/SUBSCRIPTION:**

[prenumerata@wydawnictwo-aluna.pl](mailto:prenumerata@wydawnictwo-aluna.pl)

---

© Copyright by Aluna

Wydanie czasopisma Acta Balneologica w formie papierowej jest wersją pierwotną (referencyjną).  
Redakcja wdraża procedurę zabezpieczającą oryginalność publikacji naukowych oraz przestrzega zasad  
recenzowania prac zgodnie z wytycznymi Ministerstwa Nauki i Szkolnictwa Wyższego.

# SPIS TREŚCI/CONTENTS

## ORIGINAL ARTICLES/PRACE ORYGINALNE

- Włodzisław Kuliński, Katarzyna Szymczyk  
**Postępowanie fizykalne u chorych po przebytych krwotoku podpajęczynówkowym. Studium kliniczne i społeczne**  
*Physical Therapy in Patients After Subarachnoid Haemorrhage. Clinical and Social Study* 5
- Agnieszka Jankowska, Paulina Klimkiewicz, Sylwia Krukowska, Marta Woldańska-Okońska  
**Assessment of the Impact of Training on the Stabilometric Platform Using the Biofeedback Method on Improving Balance and Functional Efficiency of Patients After a Stroke**  
*Ocena wpływu treningu na platformie stabilometrycznej z wykorzystaniem metody biofeedbacku na poprawę równowagi i sprawności funkcjonalnej u chorych po udarze mózgu* 15
- Denys N. Khramtsov, Olexandr N. Stoyanov, Tetiana N. Muratova, Olexandr R. Pulyk  
**Neurorehabilitation in the Early Recovery Period of Ischemic Stroke. Pharmacology Support**  
*Neurorehabilitacja we wczesnym okresie udaru niedokrwiennego mózgu. Wsparcie farmakologiczne* 22
- Ihor Vypasnyak, Bogdan Mytskan, Serhiy Popel, Tetyana Mytskan, Iryna Ivanyshyn, Volodymyr Banakh, Lyubov Levandovska, Viktoria Gryb  
**Non-medicinal Correction of Motor Disorders of the Valley of the Foot in Multiple Sclerosis**  
*Niefarmakologiczne metody korekcji zaburzeń motoryki sklepienia stopy u pacjentów ze stwardnieniem rozsianym* 26
- Liliya S. Babinets, Halyna M. Sasyk, Iryna M. Halabitska, Victoria R. Mykuliak  
**Possibilities of Complex Rehabilitation of Patients with Type 2 Diabetes and Concomitant Chronic Pancreatitis in Ambulatory Practice**  
*Możliwości kompleksowej rehabilitacji pacjentów z cukrzycą typu 2 i współwystępującym przewlekłym zapaleniem trzustki w praktyce ambulatoryjnej* 33
- Inna I. Torianyk  
**Etiopathogenetic Assessment of Tick Skin Injuries in Vacationers of Suburban Resorts and Tourists of Ukraine as a Component of a Complex Diagnostic Algorithm of Babesiosis**  
*Ocena etiopatogenetyczna zmian skórnych wywołanych przez kleszcze u wczasowiczów podmiejskich kurortów i turystów na Ukrainie jako element złożonego algorytmu diagnostycznego babeszjozy* 38
- Grygoriy P. Griban, Vladyslav A. Smiiianov, Natalia A. Lyakhova, Pavlo P. Tkachenko, Alla M. Harlinska, Nadya Yu. Dovgan, Ihor Yo. Malynskyi, Yurii A. Brytan  
**The Impact of Nutritional Quality on the Students' Health**  
*Wpływ jakości odżywiania na stan zdrowia studentów* 43
- Mateusz W. Romanowski, Anna Kostiurow, Wojciech Strzelecki, Piotr Poniewierski, Kinga Litwin, Ewa Mojs, Włodzimierz Samborski  
**Czy osoby chorujące na reumatoidalne zapalenie stawów potrzebują wsparcia psychicznego ze względu na ryzyko wystąpienia depresji?**  
*Do People with Rheumatoid Arthritis Need Mental Support?* 55

## REVIEWS ARTICLES/PRACE POGLĄDOWE

- Anna Kokocińska, Przemysław Adamczyk, Irena Ponikowska  
**Co morsowanie ma wspólnego z balneoterapią**  
*What does Winter Swimming Have to do with Balneotherapy?* 60
- Sebastian Szyper, Paweł Zalewski  
**Evaluation of the Autonomic Nervous System Changes and Temporal-Spatial Gait Analysis in Patients with Ischemic Stroke Subjected to Neurorehabilitation Conventional Methods and Using Special. Literature Review**  
*Ocena zmian aktywności autonomicznego układu nerwowego i czasowo-przestrzenna analiza chodu u pacjentów po udarze niedokrwiennym mózgu, poddanych neurorehabilitacji tradycyjnymi metodami terapii i wg metod specjalnych. Przegląd piśmiennictwa* 65

## PRACA KAZUISTYCZNA/CASE REPORT

- Agnieszka Maruszewska, Lech Panasiuk, Katarzyna Bryzek-Michalak  
**Rehabilitacja w zespole Devica. Opis przypadku**  
*Rehabilitation in Devica's Syndrome. Case Report* 71

# Neurorehabilitation in the Early Recovery Period of Ischemic Stroke. Pharmacology Support

## Neurorehabilitacja we wczesnym okresie udaru niedokrwiennego mózgu. Wsparcie farmakologiczne

DOI: 10.36740/ABAL202101103

Denys N. Khramtsov<sup>1</sup>, Olexandr N. Stoyanov<sup>1</sup>, Tetiana N. Muratova<sup>1</sup>, Olexandr R. Pulyk<sup>2</sup><sup>1</sup>Odesa National Medical University, Odesa, Ukraine<sup>2</sup>Uzhhorod National University, Uzhhorod, Ukraine

### SUMMARY

**Aim:** The aim of the study was to evaluate the clinical outcome in the use of neuroprotective agents in the acute period of ischemic stroke.**Material and Methods:** The study was performed on the basis of the stroke of the Center for Reconstructive and Rehabilitation Medicine (University Clinic) of the Odesa National Medical University. A retrospective analysis of clinical outcomes of 115 patients with acute stroke was conducted.**Results:** An average NIHSS score at discharge was  $4.1 \pm 0.1$  points when treated with no refinery, then it reached  $3.6 \pm 0.1$  points when using peptidergic drugs, and  $3.4 \pm 0.1$  when using D-fdf.  $3.1 \pm 0.1$  points. When using D-FDF, the MMSE score was  $3.5 \pm 0.1$  points, whereas when using cholinergic agents, this index did not exceed  $26.9 \pm 1.5$  points, and when using peptidergic agents -  $26.8 \pm 1.4$  points.**Conclusion:** The use of neuroprotective agents positively affects the effectiveness of neuro-rehabilitation in patients with acute stroke. The best results in three months after the hospitalization were obtained for peptidergic agents and D-fructose-1,6-diphosphate.**Key words:** stroke, neuroprotection, neurorehabilitation, treatment

### STRESZCZENIE

**Cel:** Celem badania klinicznego była ocena efektywności rehabilitacji poudarowej przy dołączeniu środków neuroprotekcyjnych w ostrym okresie udaru niedokrwiennego mózgu.**Material i metody:** Badanie przeprowadzono na oddziale udaru mózgu Centrum Medycyny Rekonstrukcyjnej i Rehabilitacyjnej (Klinika Uniwersytecka) Narodowego Uniwersytetu Medycznego w Odessie. Przeprowadzono analizę retrospektywną wyników klinicznych u 115 pacjentów z udarem mózgu.**Wnioski:** Udowodniono, że stosowanie środków neuroprotekcyjnych ma pozytywny wpływ na skuteczność neurorehabilitacji pacjentów po udarze. Trzy miesiące po hospitalizacji najlepsze wyniki uzyskano u pacjentów ze wsparciem lekami peptyderycznymi i D-fruktozo-1,6-difosforanem.**Słowa kluczowe:** udar mózgu, neuroprotekcja, neurorehabilitacja, leczenie

Acta Balneol, TOM LXIII, Nr 1(163);2021:22-25

### INTRODUCTION

According to WHO, stroke remains the second most common cause of death (12% of all deaths) and the leading cause of disability. In 2013, nearly 6.5 million people died from stroke in the world, and in ten years the number of stroke deaths will increase to 7.8 million per year [1]. After a stroke, a third of patients die within the first year and about a third of patients remain dependent on outside help forever. Due to the severe socio-economic impact of a stroke, the prevention and treatment of acute cerebrovascular pathology in the majority of developed nations are formally recognized as a priority for health [1, 2].

According to the indicators of incidence of acute disorders of cerebral circulation and mortality from stroke, Ukraine ranks as one of the first places in Europe (Fig. 1). According to official statistics, 100-110 thousand cases of stroke occur every year (more than a third of them are of working age patients) [2]. The death rate reaches 138.0 cases per 100,000 population, which corresponds to close to 55,500 deaths per year [1-3].

Since the late 1990s, the Stroke Unit has been the "gold standard" for stroke care [4-6]. The priority for organizing and expanding the stroke block network in Europe was proclaimed by the Helsingborg Consensus in 1996 and 2006

and the recently approved Munich Consensus 2018, which adopted a plan for action to prevent and treat stroke by 2030, with final approval expected in May 2020. According to this document, by 2030, the absolute number of new stroke cases in Europe should be reduced by 10%, and at least 90% of all patients with stroke should receive first-line care in stroke units [3] (Figure 1).

The pathophysiology of ischemic stroke is complex and has not yet been sufficiently studied [7]. With a prolonged reduction of cerebral perfusion, irreversible ischemic damage to brain tissue develops. The zone of the nucleus of the infarction of the brain is surrounded by ischemic tissue - the area of the penumbra, in which energy metabolism is still preserved, but functional changes of neurons are already being occurred. Under unfavorable conditions, the infarction zone may increase than brain edema raises. Both cytotoxic and ionic mechanisms, as well as vasogenic swelling, play a role in the development of edema. Against this background, the processes of glutamate and calcium-induced excitotoxicity are realized, the processes of lipid peroxidation are enhanced, the production of nitric oxide and free radicals is increased. Activation of glia ischemia results in a secondary local inflammatory process that enhances the permeability of the blood-brain barrier. The described changes are accompanied by activation of apoptosis [7, 8]

The management of patients after acute stroke involves the use of a whole range of different medical methods, including drug therapy, at all stages of the rehabilitation process, starting with the acute period of the disease, when the patient's rehabilitation potential is largely determined.

As the process of stroke recovery is multicomponent and multidisciplinary, drug therapy consists of basic (correction of essential vital functions) and reperfusion therapy (use of anticoagulants, antiplatelet agents and tissue plasminogen activators); neuroprotection (prevention, interruption and reduction of adverse effects on the brain), as well as secondary prevention and treatment of post-stroke conditions, along with neurorehabilitation measures [9].

The results of numerous clinical trials have led to a change in the concept of neuroprotection in stroke. Any measures aimed at reducing neuronal losses in acute ischemic stroke (reperfusion, antithrombotic agents, normalization of physiological functions) can be considered as indirect neuroprotection [9, 10]. In a more narrow sense, neuroprotection is considered to be the use of drugs that act directly on brain cells (cytoprotection) and can play an independent role in the treatment of ischemic stroke in the acute stage [10, 11, 12, 13]. However, the clinical efficacy of various neuroprotective agents is still a matter of debate [5, 9].

## AIM

The aim of the study was to evaluate clinical outcomes with the use of non-protective agents in the acute ischemic stroke period.

## MATERIAL AND METHODS

The study was performed at the stroke unit of the Center for Reconstructive and Rehabilitation Medicine (University Clinic) of the Odessa National Medical University. A retrospective analysis of clinical outcomes of 115 patients treated for ischemic stroke during 2017-2019 was conducted. Inclusion criteria:




Figure 1. Stroke Mortality in the World (WHO, 2017) [5]

NIHSS at the time of admission - 5-15 points, consent to participate in the study. Exclusion criteria: severe stroke, multiple organ failure, presence of severe comorbidity, hyperphosphatemia, refusal to participate in the study.

Treatment efficacy was evaluated by changes in NIHSS and mRS at the time of discharge, and further evaluated the dynamics of indicators on the MMSE and CGI-I scales after three months [14]. Statistical processing was performed using the non-parametric Wilcoxon-Mann-Whitney test using the Statistica 13.0 software (TIBCO, USA) [15].

## RESULTS AND DISCUSSION

The average age of the patients who participated in the study was  $56.2 \pm 1.8$  years. Among the patients, men (65 or 56.5%) were slightly predominant, 50 were women (43.5%). The average NIHSS score at the time of admission was  $12.2 \pm 0.9$  points. The level of adaptive capacity of the body in patients was significantly reduced - an average of  $2.1 \pm 0.1$  per mRS. Symptoms of moderate cognitive deficits were found in 36.5% of patients, the mean MMSE score was  $24.6 \pm 1.2$ .

According to the medical records, the majority of patients received certain neuroprotective drugs (Figure 2), including peptidergic (cerebrolysin, actovegin, cortexin, cerebrocurin), cholinergic (cyticolin, choline alfoscerate), macroergic precursors (D-fructose-1,6-diphosphate, D-FDP). Only 9.6% of patients did not have prescriptive medications in their appointments, infusion therapy contained predominantly volumetric controls, as well as drugs for the correction of electrolyte exchange disorders and, if necessary, antihypertensive agents.

When evaluating the effectiveness of treatment, depending on the type of used neuroprotective compounds (Table 1), it was found that in three months after hospitalization the best results were obtained with the use of peptidergic agents and D-FDP.

Thus, if the average NIHSS score at discharge was  $4.1 \pm 0.1$  points when treated with no refinery, then it reached  $3.6 \pm 0.1$  points when using peptidergic drugs, and  $3.4 \pm 0.1$  when using D-fdf.  $3.1 \pm 0.1$  points. As for the mRS score, it was virtually indistinguishable in patients receiving different neurorehabilitation treatment ( $p > 0.05$ ), which may be explained by the small number of observations.

The effect of drug neuroprotection on the level of cognitive deficits is noteworthy. When using D-FDF, the MMSE score was  $3.5 \pm 0.1$  points, whereas when using cholinergic agents, this index did not exceed  $26.9 \pm 1.5$  points, and when using peptidergic agents -  $26.8 \pm 1.4$  points. These values are almost




Figure 2. Distribution of patients according to the use of neuroprotective compounds

indistinguishable from the level achieved in patients who have not received special neuroprotective agents ( $p > 0.05$ ), but the demonstrated trend is noteworthy.

With regard to the CGI index, at the end of treatment, it averaged  $3.3 \pm 0.1$  points in patients who did not receive refineries, while in patients receiving cholinergic agents it equaled  $2.5 \pm 0.1$  points, peptidergic agents -  $2.6 \pm 0.1$  points, and when using D-fdp -  $2.5 \pm 0.1$  points ( $p < 0.05$ ), which corresponds to significant changes in the state of the cognitive sphere and general social adaptations.

In our opinion, the positive effect of D-fdp on neurorehabilitation, which can be explained by the optimization of various physiological processes, including energy metabolism, ATP synthesis, oxygen transport to tissues (2,3-diphosphoglycerate), regulation of the activity of glycolysis, pH maintenance of blood and urine, is worthy of note.

The nutritional deficiency of phosphorus inherent in patients with ischemic stroke can be successfully corrected by the introduction of actively metabolized metabolites such as fructose-1,6-diphosphate. In vitro and in vivo biochemical studies also indicate that D-fdp interacts with cell membranes at pharmacological doses, accelerates the uptake of potassium cells from circulating blood, and stimulates an increase in the intracellular supply of high-energy phosphate and 2,3-diphosphoglycerate.

The principles of action of cholinergic and peptidergic agents are somewhat different - according to current ideas, the enhancement of cholinergic and peptidergic stimulation of brain structures promotes neuroplastic changes. Increased cholinergic transmission and reduction of transmitter dysfunction increases the affinity of GABA receptors and

Table 1. The results of treatment depending on the type of used neuroprotective agents

Indices	With neuroprotective agents			Without neuroprotective agents
	Cholinergic agents	Peptidergic agents	D-fdp	
NIHSS	$3,8 \pm 0,2$	$3,6 \pm 0,1^*$	$3,4 \pm 0,1^*$	$4,1 \pm 0,1$
mRS	$0,9 \pm 0,1$	$0,9 \pm 0,1$	$0,9 \pm 0,1$	$1,0 \pm 0,1$
MMSE	$26,9 \pm 1,5$	$26,8 \pm 1,4$	$27,0 \pm 1,3$	$25,7 \pm 1,4$
CGI-I	$2,5 \pm 0,1^*$	$2,6 \pm 0,1^*$	$2,5 \pm 0,1^*$	$3,3 \pm 0,1$

Note: \* differences with non-refined group were statistically significant ( $p < 0.05$ )

limits NMDA receptor hypersensitivity. Such stimulation of the mechanisms of neuroplasticity and natural neurogenesis leads to structural and functional neuroreparation, which is the key to rapid and successful rehabilitation after the stroke.

## CONCLUSIONS

The use of neuroprotective agents has a positive effect on the effectiveness of the neurorehabilitation of patients with ischemic stroke.

The best results are obtained for peptidergic agents and D-FDP.

## References

- Global status report on noncommunicable diseases 2014 <http://www.who.int/nmh/publications/ncd-status-report-2014/en/10>. Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. *J Med Life*. 2017 Jul-Sep;10(3):153-160.
- Muratova T, Khramtsov D, Stoyanov A, Vorokhta Y. Clinical epidemiology of ischemic stroke: global trends and regional differences. *Georgian Med News*. 2020 Feb;(299):83-86.
- Action Plan for Stroke in Europe 2018-2030 <https://eso-stroke.org/eso/action-plan-stroke-europe-2018-2030>
- Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator. *J Stroke Cerebrovasc Dis*. 2017 Sep;26(9):1996-2003.
- Duncan PW, Bushnell CD, Rosamond WD, Jones Berkeley SB, Gesell SB, D'Agostino RB Jr, Ambrosius WT, Barton-Percival B, Bettger JP, Coleman SW, Cummings DM, Freburger JK, Halladay J, Johnson AM, Kucharska-Newton AM, Lundy-Lamm G, Lutz BJ, Mettam LH, Pastva AM, Sissine ME, Vetter B. The Comprehensive Post-Acute Stroke Services (COMPASS) study: design and methods for a cluster-randomized pragmatic trial. *BMC Neurol*. 2017 Jul 17;17(1):133
- Muñoz Venturelli P, Robinson T, Lavados PM, Olavarría VV, Arima H, Billot L, Hackett ML, Lim JY, Middleton S, Pontes-Neto O, Peng B, Cui L, Song L, Mead G, Watkins C, Lin RT, Lee TH, Pandian J, de Silva HA, Anderson CS; HeadPoST Investigators. Regional variation in acute stroke care organisation. *J Neurol Sci*. 2016 Dec 15;371:126-130.
- Tytov B.V., Matveeva N.A., Martynov M.Yu. et al. Ysh emycheskyy ynsult kak kompleksnoe polygennoe zabolevaniye [Ischemic stroke as a complex polygenic disease]. *Molekulyarnaya byologiya*. 2015;2(49):224. (In Russian).
- Zhongwu Liu, Michael Chopp Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. *Prog Neurobiol*. 2016 Sep; 144: 103-120.
- Putylyna M.V. Rol neyroprotektssy v ranney reabylytatsyy patsyentov posle ynsulta s pozytssy dokazatelnoy medytssyn [The role of neuroprotection in the early rehabilitation of patients after stroke from the standpoint of evidence-based medicine]. *Molekulyarnaya byologiya*. 2015; 2(49):224. (In Russian).
- Zakharov V. V., Vakhnyina N. V. Neyroprotektivnaya terapiya ostroy y khronycheskoy tserebralnoy yshemy [Neuroprotective therapy for acute and chronic cerebral ischemia]. *Farmateka*. 2016;7 (320):27-34. (In Russian).
- Li M, Zhou ZP, Sun M, Cao L, Chen J, Qin YY, Gu JH, Han F, Sheng R, Wu JC, Ding Y, Qin ZH. Reduced Nicotinamide Adenine Dinucleotide Phosphate, a Pentose Phosphate Pathway Product, Might Be a Novel Drug Candidate for Ischemic Stroke. *Stroke*. 2016 Jan;47(1):187-95
- Rachna S. Pandya, Lijuan Mao, Hua Zhou, Shuanhu Zhou, Jiang Zeng, A. John Popp, Xin Wang Central Nervous System Agents for Ischemic Stroke: Neuroprotection Mechanisms *Cent Nerv Syst Agents Med Chem*. 2011 Jun 1; 11(2): 81-97.
- Busner J, Targum SD. The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice. *Psychiatry (Edgmont)*. 2007;4(7):28-37.
- Khalafyan A. A. *Statistica 6. Matematycheskaya statystyka s elementamy teoryy veroyatnosti [Mathematical statistics with elements of probability theory]*. Moskva: Bynom; 2011-326 s. (In Russian).

**Received:** 19.10.2020

**Accepted:** 12.02.2021

### Conflict of interest:

The Authors declare no conflict of interest

---

### ADDRESS FOR CORRESPONDENCE:

**Denys N. Khramtsov**

Odessa National Medical University,  
Valikhovskiy lane, 2, Odesa, 65082, Ukraine  
phone: +380973126185  
e-mail: dionis\_hr@live.ru

### ORCID ID and AUTHORS CONTRIBUTION

0000-0002-5289-5542 – Denys N. Khramtsov (A, B, C, D, E, F)

0000-0002-3375-0452 – Olexandr N. Stoyanov (D, E, F)

0000-0001-6573-6180 – etiana N. Muratova (B, D, E, F)

0000-0002-8717-047X – Olexandr R. Pulyk (C, E, F)

---

A – Research concept and design, B – Collection and/or assembly of data, C – Data analysis and interpretation, D – Writing the article, E – Critical revision of the article, F – Final approval of article